Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

被引：0

作者：

Hui, Liu ^{[1
]}

Xuan, Li ^{[1
]}

Lin, Ren ^{[1
]}

Deng, Lan ^{[2
]}

Huang, Fen ^{[1
]}

Fan, Zhiping ^{[1
]}

Nie, Danian ^{[3
]}

Li, Xudong ^{[4
]}

Liang, Xinquan ^{[5
]}

Xu, Dan ^{[1
]}

Zhang, Yu ^{[1
]}

Xu, Na ^{[2
]}

Ye, Jieyu ^{[2
]}

Jin, Hua ^{[1
]}

Lin, Dongjun ^{[4
]}

Ma, Liping ^{[6
]}

Sun, Jing ^{[2
]}

Huang, Xiaojun ^{[7
]}

Liu, Qifa ^{[1
]}

机构：

[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China

[2] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, SUN Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China

[4] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hematol, Guangzhou, Guangdong, Peoples R China

[5] Southern Med Univ, Peoples Hosp Chenzhou 1, Dept Hematol, Chenzhou, Peoples R China

[6] Sun Yat Sen Univ, Sun Yat Sen Mem, Guangzhou, Guangdong, Peoples R China

[7] Peking Univ Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Peking Univ Inst Hematol, Beijing, Peoples R China

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126901

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3303

引用

页数：3

共 11 条

[1] BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
Andolina, Jeffrey R.
ACTA HAEMATOLOGICA, 2015, 134 (02) : 69 - 70
[2] Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus
Couban, S.
Savoie, L.
Abou Mourad, Y.
Leber, B.
Minden, M.
Turner, R.
Palada, V.
Shehata, N.
Christofides, A.
Lachance, S.
CURRENT ONCOLOGY, 2014, 21 (02) : E265 - E309
[3] Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study
Anna Candoni
Davide Lazzarotto
Alessandro Rambaldi
Maria Vittoria Dubbini
Paola Bresciani
Alessandro Busca
William Arcese
Anna Paola Iori
Roberto Sorasio
Giuseppe Irrera
Renato Fanin
Fabio Ciceri
Francesca Bonifazi
Bone Marrow Transplantation, 2022, 57 : 834 - 836
[4] Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study
Candoni, Anna
Lazzarotto, Davide
Rambaldi, Alessandro
Dubbini, Maria Vittoria
Bresciani, Paola
Busca, Alessandro
Arcese, William
Iori, Anna Paola
Sorasio, Roberto
Irrera, Giuseppe
Fanin, Renato
Ciceri, Fabio
Bonifazi, Francesca
BONE MARROW TRANSPLANTATION, 2022, 57 (05) : 834 - 836
[5] The Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Elderly Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) in the Era of Tyrosine Kinase Inhibitor (TKI) : A Single Institute Experience
Doki, Noriko
Igarashi, Aiko
Najima, Yuho
Kobayashi, Takeshi
Kakihana, Kazuhiko
Sakamaki, Hisashi
Ohashi, Kazuteru
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S279 - S279
[6] Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis
Zhang, Wanhua
Kuang, Pu
Liu, Ting
PLOS ONE, 2020, 15 (12):
[7] Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study
Soverini, Simona
Bavaro, Luana
Martelli, Margherita
De Benedittis, Caterina
Papayannidis, Cristina
Percesepe, Antonio
Laginestra, Maria Antonella
Sica, Simona
Sora, Federica
Albano, Francesco
Pagano, Livio
Criscuolo, Marianna
Galimberti, Sara
Salvucci, Marzia
Annunziata, Mario
Marconi, Giovanni
Curti, Antonio
Russo, Sabina
Imovilli, Annalisa
Mannina, Daniele
Ferrero, Dario
Stulle, Manuela
Basilico, Claudia
Abruzzese, Elisabetta
Mignone, Flavio
Pileri, Stefano A.
Martinelli, Giovanni
Cavo, Michele
BLOOD, 2018, 132
[8] Optimal Interval for Detection of Molecular Relapse after Stop of Tyrosine Kinase Inhibitor (TKI) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Caliculated By Kinetics of BCR-ABL Transcripts
Miyamura, Koichi
Osaki, Masahide
Goto, Tatsunori
Morishita, Takanobu
Ozawa, Yukiyasu
BLOOD, 2020, 136
[9] Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Cazzaniga, Giovanni
De Lorenzo, Paola
Alten, Julia
Roettgers, Silja
Hancock, Jeremy
Saha, Vaskar
Castor, Anders
Madsen, Hans O.
Gandemer, Virginie
Cave, Helene
Leoni, Veronica
Koehler, Rolf
Ferrari, Giulia M.
Bleckmann, Kirsten
Pieters, Rob
van der Velden, Vincent
Stary, Jan
Zuna, Jan
Escherich, Gabriele
zur Stadt, Udo
Arico, Maurizio
Conter, Valentino
Schrappe, Martin
Valsecchi, Maria Grazia
Biondi, Andrea
HAEMATOLOGICA, 2018, 103 (01) : 107 - 115
[10] Activity of the ABL-tyrosine kinase inhibitor Glivec (STI571) in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation (allo-SCT).
Ottmann, OG
Wassmann, B
Pfeifer, H
Scheuring, U
Thiede, C
Brueck, P
Binckebank, A
Atta, J
Martin, H
Gschaidmeier, H
Hoelzer, D
BLOOD, 2001, 98 (11) : 589A - 590A

← 1 2 →